SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2052)4/5/1999 3:12:00 PM
From: Steve Harmon  Respond to of 2742
 
Rick,

Do you think we will hear the word "ENHANCED" again?

Steve



To: scaram(o)uche who wrote (2052)4/13/1999 1:45:00 PM
From: Steve Harmon  Read Replies (2) | Respond to of 2742
 
Attn. mgr. of Cistron(and Cistron's bod):

KeraVision's CEO is a few blocks away in New Jersey. Call him. KERA is paying a 20-30% premium for TSND's cash.

That equates to 70 cent a share to Cistron's shareholders for just our cash.

Current bid>.20



To: scaram(o)uche who wrote (2052)4/24/1999 2:44:00 PM
From: Steve Harmon  Respond to of 2742
 
Have you ever heard of a Bankruptcy Chapter 11 CRAMDOWN?



To: scaram(o)uche who wrote (2052)6/30/1999 2:16:00 PM
From: Walter Morton  Respond to of 2742
 
Future of Anti-Cytokine Therapies

Blocking TNF and IL-1 together
Blocking TNF and IL-1 in hear failure
Pretreatment before CABG and other by-pass Surgery
In stroke and acute MI
Return to sepsis trials
Adjuvant therapy in cancer

That's just some of the new info added to the website last week.

emedtrade.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News